Novo Nordisk AS - Company Profile

Powered by

All the data and insights you need on Novo Nordisk AS in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Novo Nordisk AS Strategy Report

  • Understand Novo Nordisk AS position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Novo Nordisk AS: Overview

Select Item

Related keylists

View more

Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for haemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

 Gain a 360-degree view of Novo Nordisk AS and make more informed decisions for your business Gain a 360-degree view of Novo Nordisk AS and make more informed decisions for your business Find out more
Headquarters Denmark
Address Novo Alle 1, Bagsvaerd, 2880
Website www.novonordisk.com
Telephone 45 44 448888
No of Employees 63,370
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange NOVO B (CPH)
Revenue (2022) $33.7B 31.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 50.7% (2022 vs 2021)
Market Cap* $431.3B
Net Profit Margin (2022) XYZ 14.8% (2022 vs 2021)
* As of and is in US$
View Novo Nordisk AS financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Novo Nordisk AS premium industry data and analytics

1,400+

Clinical Trials

Determine Novo Nordisk AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

690+

Catalyst Calendar

Proactively evaluate Novo Nordisk AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

680+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novo Nordisk AS’s relevant decision makers and contact details.

210+

Pipeline Drugs

Identify which of Novo Nordisk AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

140+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

50+

Marketed Drugs

Understand Novo Nordisk AS’s commercialized product portfolio to stay one step ahead of the market.

40+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

40+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Novo Nordisk AS and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Investigators

Review investigator profiles and find information on trial contacts across Novo Nordisk AS, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

13+

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Novo Nordisk AS (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novo Nordisk AS’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Diabetes Delivery Systems: Rivfloza
Insulin Pens Tresiba
Injection Needles Ryzodeg
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Novo Nordisk AS portfolio and identify potential areas for collaboration Understand Novo Nordisk AS portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Plans/Strategy In March, the company announced its plans to acquire Cardior Pharmaceuticals, a biotech company.
2024 Regulatory Approval In March, the company secured expanded approval from the US FDA for Wegovy to treat stroke and heart attacks.
2024 Plans/Strategy In March, Novo Holdings announced its plans to open a new office in Mumbai, India.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Novo Nordisk AS Johnson & Johnson F. Hoffmann-La Roche Ltd Merck & Co Inc Pfizer Inc
Headquarters Denmark United States of America Switzerland United States of America United States of America
City Bagsvaerd New Brunswick Basel Kenilworth New York
State/Province - New Jersey - New Jersey New York
No. of Employees 63,370 131,900 103,605 72,000 88,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Helge Lund Chairman Executive Board 2018 62
Lars Fruergaard Jorgensen President; Chief Executive Officer Senior Management 2017 58
Karsten Munk Knudsen Chief Financial Officer; Executive Vice President Senior Management 2018 53
Marcus Schindler Chief Scientific Officer; Executive Vice President - Research & Early Development Senior Management 2021 58
Henrik Poulsen Vice Chairman Executive Board 2021 57
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Novo Nordisk AS key executives to enhance your sales strategy Gain insight into Novo Nordisk AS key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward